Predicting toxicity in the drug development pipeline

July 19, 2012

University College Dublin researchers have reported in Molecular & Cellular Proteomics on a proof-of-principle study that may benefit the pharmaceutical industry in the future by providing a roadmap for large scale pre-clinical toxicology biomarker verification studies.

It is not currently possible to predict accurately and at an early stage whether there are toxicity issues with candidate drugs. This shortcoming of existing toxicology evaluation methods can not only create a bottleneck in the pipeline but can sometimes lead to the withdrawal of drugs from the market.

The study involved the molecular profiling of models that had been exposed to known toxic insults in an effort to derive the associated biomarker signatures. Forty-eight candidate biomarkers of liver toxicity were assembled from a discovery proteomics screen of liver in a hepatotoxicant treated rat model using label free liquid chromatography mass spectrometry (LC-MS); a previous transcriptomics study of the sample samples and from literature sources.

The team developed and optimised a selected reaction monitoring assay (SRM) in order to quantify the proteins in this putative biomarker panel. This revealed a panel highly enriched for proteins that had been changed significantly as a result of toxicant exposure .   

Dr. Ben Collins, first author and Agilent UCD Newman Fellow, explains, “The idea was to use transcriptomics,  and proteomics and to combine the data to provide earlier markers . Although this study focused on one hepatotoxic compound, there is sufficient flexibility in the approach used to allow medium to high throughput for large scale verification studies involving large numbers of well- defined toxicants and ultimately for more sensitive toxicology evaluation for drugs under early development”.

Team leader and corresponding author, Professor Steve Pennington adds, “We are now working to extend this approach to more readily accessible sample types, such as blood, and are applyijng it in other studies for diagnostics for chronic conditions, such as cancer, cardiovascular disease, and arthritis. With supporti from Agilent are now establishing a dedicated lab to undertake these SRM-based validation studies”.

Explore further: GEN reports on nanotechology's impact on mass spectrometry

More information: Collins, BC et al; Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach. Molecular & Cellular Proteomics (2012) doi: 10.1074/mcp.M111.016493

Related Stories

GEN reports on nanotechology's impact on mass spectrometry

August 4, 2011
A move toward smaller and smaller sample sizes is leading to a new generation of mass spectrometry instrumentation, reports Genetic Engineering & Biotechnology News (GEN). From a specific application point of view, novel ...

Cancer biomarkers re-evaluated

July 19, 2012
(Medical Xpress) -- Researchers from ETH Zurich have developed a procedure to test the clinical benefits of cancer biomarkers. The method could radically shorten the path from the lab to their application.

Polyphenol-rich diet could reduce cardiovascular risk

December 15, 2011
(Medical Xpress) -- A diet high in polyphenols could help reduce the risk of cardiovascular disease and associated health risks, according to a new study by the University of Glasgow.

New prostate cancer biomarkers move closer to clinical use

June 17, 2011
Conway Fellow, Professor William Watson and Professor John Fitzpatrick, UCD School of Medicine and Medical Science and Mater Misericordiae University Hospital recently received a translational research award for the validation ...

Recommended for you

Engineered protein treatment found to reduce obesity in mice, rats and primates

October 19, 2017
(Medical Xpress)—A team of researchers with pharmaceutical company Amgen Inc. report that an engineered version of a protein naturally found in the body caused test mice, rats and cynomolgus monkeys to lose weight. In their ...

New procedure enables cultivation of human brain sections in the petri dish

October 19, 2017
Researchers at the University of Tübingen have become the first to keep human brain tissue alive outside the body for several weeks. The researchers, headed by Dr. Niklas Schwarz, Dr. Henner Koch and Dr. Thomas Wuttke at ...

Cancer drug found to offer promising results in treating sepsis in test mice

October 19, 2017
(Medical Xpress)—A combined team of researchers from China and the U.S. has found that a drug commonly used to treat lung cancer in humans offers a degree of protection against sepsis in test mice. In their paper published ...

Tracing cell death pathway points to drug targets for brain damage, kidney injury, asthma

October 19, 2017
University of Pittsburgh scientists are unlocking the complexities of a recently discovered cell death process that plays a key role in health and disease, and new findings link their discovery to asthma, kidney injury and ...

Study reveals key molecular link in major cell growth pathway

October 19, 2017
A team of scientists led by Whitehead Institute has uncovered a surprising molecular link that connects how cells regulate growth with how they sense and make available the nutrients required for growth. Their work, which ...

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.